---
title: "Cadrenal Therapeutics Raises $3.0 Million in Private Placement of Pre-Funded and Common Warrants"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291465318.md"
description: "Cadrenal Therapeutics raised $3.0 million via a private placement of pre-funded and common warrants to an institutional investor. Funds are designated for working capital. Concurrently, the company signed a Registration Rights Agreement, committing to file a resale registration within 15 days and achieve effectiveness within 45 days, with specific liquidated damages for delays."
datetime: "2026-07-01T21:33:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291465318.md)
  - [en](https://longbridge.com/en/news/291465318.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291465318.md)
generator: "portal-rs"
---

# Cadrenal Therapeutics Raises $3.0 Million in Private Placement of Pre-Funded and Common Warrants

Cadrenal Therapeutics completed a private placement with an institutional investor, securing approximately $3.0 million in gross proceeds. The financing comprised 960,000 pre-funded warrants and accompanying Series C-1 and Series C-2 common warrants sold at a combined $3.1249 per pre-funded warrant and warrants, with exercise prices of $0.0001 and $3.00, respectively. The company plans to use the funds for working capital. In a concurrent Registration Rights Agreement, Cadrenal committed to file a resale registration within 15 days and achieve effectiveness within 45 days (or 75 days if fully reviewed), with liquidated damages of 1% per 30 days for certain delays, capped at 6%.

**Agreement 1: Cadrenal Therapeutics Raises $3.0 Million in Private Placement of Pre-Funded and Common Warrants**

-   **Agreement type**: Securities Purchase Agreement for private placement of warrants
-   **Counterparty**: Institutional investor
-   **Signed / Effective**: Jun 30 2026 / Jul 01 2026
-   **Duration / Termination**: N/A
-   **Reason**: Raise working capital and strengthen liquidity

**Agreement 2: Cadrenal Therapeutics Grants Resale Registration Rights to Investor Following Warrants Financing**

-   **Agreement type**: Registration Rights Agreement for resale of warrant shares
-   **Counterparty**: Institutional investor
-   **Signed / Effective**: Jun 30 2026 / Jun 30 2026
-   **Duration / Termination**: Until all registered shares are sold or freely tradable
-   **Reason**: Provide resale liquidity to investor

Original SEC Filing: Cadrenal Therapeutics, Inc. \[ CVKD \] - 8-K - Jul. 01, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [CVKD.US](https://longbridge.com/en/quote/CVKD.US.md)

## Related News & Research

- [Cadrenal Therapeutics issues 1.92 million warrants in $3 million private placement priced at $3.125 per share](https://longbridge.com/en/news/291464681.md)
- [Cadrenal Therapeutics reports Q1 results](https://longbridge.com/en/news/285574137.md)
- [ReconAfrica receives $4.97 million from warrant exercises](https://longbridge.com/en/news/296156008.md)
- [REG - Sareum Holdings PLC - Exercise of Warrants](https://longbridge.com/en/news/296362927.md)
- [Cell Impact rights issue includes warrants alongside new share issuance](https://longbridge.com/en/news/296309366.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**